Abstract HIV-1 transactivator of transcription (Tat) protein disrupts the dopamine (DA) neurotransmission by inhibiting DA transporter (DAT) function, leading to increased neurocognitive impairment in HIV-1 infected individuals. Through integrated computational modeling and pharmacological studies, we have demonstrated that mutation of tyrosine470 (Y470H) of human DAT (hDAT) attenuates Tatinduced inhibition of DA uptake by changing the transporter conformational transitions. The present study examined the functional influences of other substitutions at tyrosine470 (Y470F and Y470A) and tyrosine88 (Y88F) and lysine92 (K92M), two other relevant residues for Tat binding to hDAT, in Tat-induced inhibitory effects on DA transport. Y88F, K92M and Y470A attenuated Tat-induced inhibition of DA transport, implicating the functional relevance of these residues for Tat binding to hDAT. 
Introduction
HIV-1-associated neurocognitive disorder (HAND) that encompasses neurological and psychiatric complications remains highly prevalent within people living with HIV-1 even in the era of highly active antiretroviral therapy (Heaton et al. 2010; Simioni et al. 2010; Mothobi and Brew 2012) . It is commonly accepted that HIV-1 infection and replication within CNS system play a central role in the development of HAND (Gaskill et al. 2009 ). Substance abuse-HIV-1 comorbidity such as cocaine has been shown to increase the incidence and exacerbate the severity of HAND by enhancing viral replication (Nath et al. 2001; Ferris et al. 2008; Buch et al. 2011; Nair and Samikkannu 2012) . HAND is highly correlated with neurotoxic effects of HIV-1 viral proteins that are exuded from infected microglial cells (Bansal et al. 2000; Kaul et al. 2001; Mattson et al. 2005; Kaul and Lipton 2006) . HIV-1 transactivator of transcription (Tat), a non-structural viral protein required for productive infection of virus, is one of the major neurotoxins responsible for neurotoxicity and oxidative stress in central nervous system (Pocernich et al. 2005; Wallace et al. 2006 ). While HIV-1 virus enters the brain and produces proviral DNA in the early stage of HIV-1 infection (Nath and Clements 2011) , antiretroviral agents cannot prevent the production of HIV-1 viral proteins, such as Tat protein, in infected brain cells (McArthur et al. 2010; Nath and Clements 2011) . Tat has been detected in brains of patients with HIV-1 infection (Del Valle et al. 2000; Hudson et al. 2000; Lamers et al. 2010) , and implicated in the pathophysiology of HAND (Li et al. 2009 ). Tat interacting with cocaine exacerbates the progression of the neurocognitive impairment (Gannon et al. 2011) . Currently, there are no promising therapeutic approaches for such HIV-1-associated neurocognitive impairments.
Dysregulation of dopamine (DA) neurotransmission is associated with abnormal neurocognitive function and pathophysiology observed in HAND (Berger and Arendt 2000; Purohit et al. 2011) . DA levels are decreased in DA-rich brain areas (Sardar et al. 1996; Kumar et al. 2009 ), but increased in the CSF (Scheller et al. 2010 ) of HAND patients. The psychostimulant action of cocaine is mediated by increased extracellular DA in the brain.
The presynaptic DA transporter (DAT), which is critical for neurocognitive function (Chudasama and Robbins 2006) , is a major molecular target for both Tat and cocaine to impact the DA system (Zhu et al. 2009 ). DAT activity is strikingly reduced in HIV-1-infected patients with a history of cocaine use (Wang et al. 2004; Chang et al. 2008) . Our previous studies have shown that Tat protein and cocaine synergistically impair DAT function as demonstrated both in vivo (Harrod et al. 2008 ) and in vitro (Ferris et al. 2009; Zhu et al. 2011 ). Further we also demonstrated that Tat inhibits DA transport and reduces DAT cell surface expression in rat striatal synaptosomes (Zhu et al. 2009; Midde et al. 2012) , and directly binds to the DAT in an allosteric modulation manner (Zhu et al. 2009; Zhu et al. 2011) . Cocaine acts as a competitive DAT inhibitor and blocks DA transport activity (Beuming et al. 2008) . Importantly, the elevated DA induced by Tat and cocaine stimulates adjacent microglia, leading to increase of viral replication and Tat release (Gaskill et al. 2009 ), which has been implicated in the pathophysiology of HAND (Li et al. 2009 ). Considering oxidative stress-induced damage to dopaminergic neurons, long lasting exposure to viral proteins and elevated DA eventually lead to DAT(DA) deficit that potentiates severity and accelerates the progression of HAND (Purohit et al. 2011) . Thus, understanding of the interplay of Tat with cocaine in disrupting DAT-mediated DA neurotransmission may provide therapeutic insights into HAND in concurrent cocaine abusers.
Through computational modeling and simulations, we have begun to define how Tat through its recognition binding sites on human DAT (hDAT) potentiates cocaine-induced inhibition on DAT function, resulting in dysfunction of the DA system. For example, we have demonstrated that mutating tyrosine470 to histidine of hDAT attenuates Tat-mediated inhibition of DA uptake and leads to alteration of transporter conformational transitions (Midde et al. 2013) . In order to identify the binding pocket for Tat protein in DAT, it is necessary to identify the residues forming the crevice and understand the contribution of these recognition residues in substrate translocation, cocaine binding and conformational rearrangements in the transporter. In the current study, we investigated the role of additional substitutions at Tyr470 and other predicted potential Tat binding residues, Tyr88 and Lys92 of hDAT in Tat-induced decrease of DA translocation by generating point mutations Tyr470F (Y470F-hDAT), Tyr470A-hDAT (Y470A-hDAT), Tyr88Phe (Y88F-hDAT), Lys92Met (K92M-hDAT) and assessing their variability in function, surface expression, interaction with ligands and underlying mechanism for these alterations.
Materials and Methods

Predicting the Site for hDAT Binding with Tat
The binding structure of hDAT with HIV-1 clade B type Tat was modeled and simulated based on the nuclear m a g n e t i c r e s o n a n c e ( N M R ) s t r u c t u r e s o f Ta t (Peloponese et al. 2000) and the constructed structure of hDAT-DA complex. According to D-Y470 (D-refers to DAT, and hereafter) site-directed mutation experimental data as reported previously (Midde et al. 2013) , Y470 of hDAT is a functional recognition residue for Tatinduced inhibition of DAT transport cycle. Therefore, Y470 of hDAT is expected to closely interact with Tat. The protein docking program ZDOCK (Pierce et al. 2011 ) was used to determine the initial binding structure of the hDAT-Tat complex. A total of 220,000 potential conformations were generated based on 11 NMR structures of Tat, then all of these conformations were evaluated and ranked by ZRANK (Pierce and Weng 2007) . Top-3000 conformations selected from the proteinprotein docking process were submitted to energy minimizations, and the docked structures were ranked according to the binding affinity estimated by using the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method (Miller et al. 2012) . Then top-256 conformations were selected for further evaluation by performing molecular dynamics (MD) simulations. Based on the MD simulations, the most favourable hDAT-Tat binding mode (with the best geometric matching quality and reasonable interaction between hDAT and Tat) was identified, and the final hDAT-Tat binding structure was energy-minimized for analysis.
Construction of Plasmids
All point mutations of Tyr88, Lys92, and Tyr470 in hDAT were selected based on the predictions of the threedimensional computational modeling and simulations. Mutations in hDAT at Tyr88 and Tyr470 (tyrosine to phenylalanine, Y88F-hDAT and Y470F-hDAT) are expected to destroy the hydrogen bond only. Since methionine is nearly isosteric with lysine, substitution at Lys92 (lysine to methionine, K92M-hDAT) should abolish hydrogen bond with minimal perturbations to the native structure of the transporter. Substitution of tyrosine at 470 with alanine or tryptophan (Y470A-hDAT and Y470W-hDAT) is expected to eliminate both hydrogen bond and cation-π interactions that is similar to Y470H-hDAT, but with different spatial effects on structural organization of the transporter. All mutations in hDAT were generated based on wild type human DAT (WT hDAT) sequence (NCBI, cDNA clone MGC: 164608 IMAG E: 40146999) by site-directed mutagenesis. Synthetic cDNA encoding hDAT subcloned into pcDNA3.1+ (provided by Dr. Haley E Melikian, University of Massachusetts) was used as a template to generate mutants using QuikChange™ sitedirected mutagenesis Kit (Agilent Tech, Santa Clara CA). The sequence of the mutant construct was confirmed by DNA sequencing at University of South Carolina EnGenCore facility. Plasmids DNA were propagated and purified using plasmid isolation kit (Qiagen, Valencia, CA, USA).
Cell Culture and DNA Transfection
Chinese hamster ovary (CHO, ATCC #CCL-61) cells were maintained in F12 medium supplemented with 10 % fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and 100 μg/mL streptomycin). Pheochromocytoma (PC12, ATCC #CRL-1721) cells were maintained in Dulbecco's modified eagle medium supplemented with 15 % horse serum, 2.5 % bovine calf serum, 2 mM glutamine and antibiotics (100 U/ml penicillin and 100 μg/mL streptomycin). Both cells were cultured at 37°C in a 5 % CO 2 incubator. For hDAT transfection, cells were seeded into 24 well plates at a density of 1×10 5 cells/well. After 24 h, cells were transfected with WT or mutant DAT plasmids using Lipofectamine 2000 (Life Tech, Carlsbad, CA). Cells were used for the experiments after 24 h of transfection. (Midde et al. 2013 H]DA (in the presence of 10 μM nomifensine, final concentration) was subtracted from total uptake to calculate DAT-mediated uptake. The reaction was conducted at room temperature for 8 min and terminated by washing twice with ice cold uptake buffer. Cells were lysed in 500 μl of 1 % SDS for an hour and radioactivity was measured using a liquid scintillation counter (model TriCarb 2900TR; PerkinElmer Life and Analytical Sciences, Waltham, MA). Kinetic parameters (V max and K m ) were determined using Prism 5.0 (GraphPad Software Inc., San Diego, CA). To determine the inhibitory effects of Tat on [ 3 H]DA uptake, cells transfected with WT hDAT or mutants were preincubated with Tat 1-86 or Tat Cys22 (500 nM, final concentration) for 20 min. Tat Cys22 was used as a negative control due to its null effect on DA uptake (Zhu et al. 2009 ).
The competitive inhibition DA uptake experiments were performed in duplicate in a final volume of 500 μl. Cells in each well were incubated in 450 μl KRH buffer containing 50 μl one of final concentrations of unlabeled DA (1 nM-1 mM), GBR12909 (1 nM-10 μM), cocaine (1 nM-1 and one of 7 concentrations of unlabeled substrate DA (1 nM-100 μM), inhibitors cocaine (1 nM-100 μM) or GBR12909 (0.01 nM-1 μM) and incubated on ice for 2 h. Assays were terminated by rapid filtration onto Whatman GF/B glass fiber filters, presoaked for 2 h with assay buffer containing 0.5 % polyethylenimine, using a Brandel cell harvester. Filters were rinsed 3 times with 3 ml of ice-cold assay buffer. Radioactivity remaining on the filters was determined by liquid scintillation spectrometry.
Cell Surface Biotinylation
To determine whether DAT mutations alter DAT surface expression, biotinylation assays were performed as described previously (Zhu et al. 2005) . CHO cells transfected with hDAT and mutants were plated on 6 well plates at a density of 10 5 cells/well. Cells were incubated with 1 ml of 1.5 mg/ml sulfo-NHS-SS biotin (Pierce, Rockford, IL) in PBS/Ca/Mg buffer (In mM: 138 NaCl, 2.7 KCl, 1.5 KH 2 PO 4 , 9.6 Na 2 HPO 4 , 1 MgCl 2 , 0.1 CaCl 2 , pH 7.3). After incubation, cells were washed 3 times with 1 ml of ice-cold 100 mM glycine in PBS/Ca/Mg buffer and incubated for 30 min at 4°C in 100 mM glycine in PBS/Ca/Mg buffer. Cells were then washed 3 times with 1 ml of ice-cold PBS/Ca/Mg buffer and then lysed by addition of 500 ml of Triton X-100, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μM pepstatin, 250 μM phenylmethysulfonyl fluoride), followed by incubation and continual shaking for 20 min at 4°C. Cells were transferred to 1.5 ml tubes and centrifuged at 20,000 g for 20 min. The resulting pellets were discarded, and 100 μl of the supernatants was stored at −20°C for determining immunoreactivity of total DAT. Remaining supernatants were incubated with continuous shaking in the presence of monomeric avidin beads in Triton X-100 buffer (100 μl/tube) for 1 h at room temperature. Samples were centrifuged subsequently at 17,000 g for 4 min at 4°C, and supernatants (containing the nonbiotinylated, intracellular protein fraction) were stored at −20°C. Resulting pellets containing the avidin-absorbed biotinylated proteins (cell-surface fraction) were resuspended in 1 ml of 1.0 % Triton X-100 buffer and centrifuged at 17,000 g for 4 min at 4°C, and pellets were resuspended and centrifuged twice. Final pellets consisted of the biotinylated proteins adsorbed to monomeric avidin beads. Biotinylated proteins were eluted by incubating with 75 μl of Laemmli sample buffer for 20 min at room temperature. If further assay was not immediately conducted, samples were stored at −20°C until used.
Basal Efflux Assay
DAT-mediated basal substrate efflux was carried out, as described previously (Guptaroy et al. 2009 ). We have reported that Y470H-hDAT significantly increased DA efflux compared to WT hDAT (Midde et al. 2013) . In this study, we compared the effects of 2 types of substrates, DA or MPP + on basal efflux in WT hDAT and mutants. The MPP + was chosen because MPP + has less diffusive properties than DA in heterologous expression systems (Scholze et al. 2001) . CHO cells were seeded into 24 well plates and transfected with WT hDAT and mutants. Twenty four hours after transfection cells at a density of 10 5 cells/well were washed 3 times with KRH buffer and preloaded with [ 
Results
Structural Indications for the new Experimental Results
As shown in the typical binding structure of the MDsimulated hDAT-Tat complex ( Fig. 1) , key intermolecular interactions between hDAT and Tat include: (1) aromatic side chain of D-Y470 interacting with the positively charged N-terminus of T-M1 (T-refers to Tat, and hereafter) through cation-π interaction, (2) hydroxyl group of D-Y88 side chain forming a hydrogen bond with T-K19 side chain, and (3) D-K92 side chain forming a hydrogen bond with the carbonyl of the main chain of T-P18. Based on these interactions in the hDAT-Tat binding mode, eliminating the cation-π interaction between D-Y470 and T-M1 by mutating Y470 into a non-aromatic residue such as histidine or alanine would significantly weaken the binding between hDAT and Tat. On the contrary, the Y470F mutation on hDAT would not affect the cation-π interaction and, thus, should not significantly influent the binding affinity between hDAT and Tat. In addition, in light of the binding structure, mutating D-Y88 and D-K92 into residues without hydrogen-bonding capacity would also weaken the binding between DAT and Tat. As a result, the Y88F or K92M mutation on hDAT would be expected to decrease the binding between hDAT and Tat. These computational predictions are confirmed by the obtained experimental data (see below).
Furthermore, residues D-Y470, D-K92, and D-Y88 are also involved in the function of hDAT regarding the DA uptake. Based on the MD-simulated hDAT-Tat binding structure, we noted that residue Y470 of hDAT is a key component of a hydrophobic region, which is critical for stabilizing the compact structure of hDAT (Fig. 2) . As a result, any significant change in the hydrophobic property or shape of Y470 (through mutation on Y470) would disturb the function of hDAT. Thus, the Y470H and Y470A mutation could decrease the V max of hDAT transporting function, whereas the Y470F mutation would not influence it. In addition, residues Y88, K92, and D313 also help to stabilize transmembrane helix 1b (TM1b) and transmembrane helix 6a (TM6a) through hydrophobic or electrostatic intramolecular interactions, which makes hDAT kept compact and ready for the conformational conversion associated with the DA transporting by hDAT. Specifically, the positively charged side chain of D-K92 forms a strong hydrogen bond with the negatively charged side chain of D-D313. As observed in our MD simulation, TM1b and TM6a move together during the conformational conversion associated with the DA transporting. Therefore, the hydrogen bond between D-K92 and D-D313 helps to synchronize the motion of TM1b and TM6a and, consequently, decrease the energy barrier of the conformational conversion. Hence, the K92M mutation would negatively impact the transporting kinetics of DA, i.e., decreasing the V max . Besides, the aromatic ring of the Y88 side chain is sandwiched between TM1b and extracellular loop 4 (EL4) in a hydrophobic region. As a result, the Y88F mutation would not expect to influence the function of hDAT, i.e., no significant change on V max . These computational insights are also consistent with the experimental data obtained for the K92M and Y88F mutants (see below). We have demonstrated that mutation of tyrosine (Y470H) in hDAT displayed a decrease in the V max values of [ 3 H]DA uptake under a control condition (Midde et al. 2013) . To further determine whether other substitutions at tyrosine 470 residue show differential effects on the basal DA transport, two mutations at this residue (tyrosine to phenylalanine, Y470F and tyrosine to alanine, Y470A) were generated by sitedirected mutagenesis. We determined the pharmacological profiles of [ 3 H]DA uptake in PC12 cells transfected with WT hDAT or these mutants. As shown in Fig. 3a , compared to WT hDAT (15.7±0.9 pmol/min/10 5 cells), the Y470A-hDAT displayed a decrease in the V max values [1.2± 0.2 pmol/min/10 5 cells, t (6) =23, p<0.001, unpaired Student's t test], whereas the Y470F-hDAT did not alter the V max and the K m values.
As predicted by our computational modeling and simulations, Tyr88, Lys92 and Tyr470 in hDAT are associated to play a critical role in intermolecular interaction between Tat and DAT. Two mutations in hDAT (tyrosine to phenylalanine, Y88F-hDAT and lysine to methionine, K92M-hDAT) were generated by site-directed mutagenesis. As shown in Table 1 and Fig. 4a , the V max values were decreased in K92M-hDAT (4.5± 1.7 pmol/min/10 5 cells, t (5) =3.3, p< 0.05, unpaired Student's t test) but not altered in Y88F-hDAT (14.8±3.7 pmol/min/10 5 cells) compared to WT hDAT (15.7 ± 0.9 pmol/min/10 5 cells). No difference in the K m values was observed. WIN 35,428 binding site shares pharmacological identity with the DA uptake carrier and is part of the cocaine binding domain (Pristupa et al. 1994) . We also determined the effects of these mutants on the possible relationship between the binding site of Tat on DAT and the WIN 35,428 binding site. As shown in Fig. 2 Structural details of residues Y470, K92, and Y88 in the MDsimulated hDAT-Tat binding structure. Protein hDAT is represented as cyan ribbon, and its residues Y470, K92, Y88, and D313 are shown in sticks colored in green. The hydrogen bond between K92 and D313 is represented as a dashed line with the key distance given; the hydrogen bond favorably connects M1b with TM6a in hDAT (Table 2) , the apparent affinity (IC 50 ) for DA was decreased in Y88F-hDAT (2071± 340 nM, t (8) =3.5, p<0.01) and K92M-hDAT (4211±118 nM, t (8) =2.7, p<0.05), respectively, compared to than the WT hDAT (827±120 nM). However, the potencies of cocaine were increased in Y88F-hDAT (85 ± 60 nM, t (8) = 5.8, p<0.001) but not in K92M-hDAT compared to WT hDAT (150±8.6 nM). No difference in IC 50 of GBR 12909 for inhibiting [
3 H]WIN 35,428 binding was found among Y88F-hDAT, K92M-hDAT and WT hDAT.
To determine whether these mutations of hDAT alter DAT surface expression, the immunoreactivity of total DAT and surface DAT in CHO cells transfected with WT or Y470F-hDAT, Y470A-hDAT, Y88F-hDAT or K92M-hDAT was examined using cell surface biotinylation followed by Western blotting. As shown in Fig. 3b , no difference in the ratio of surface DAT (biotinylated DAT) to total DAT between WT hDAT and Y470F-hDAT (biotinylated/total: WT, 0.93±0.09; and Y470F, 0.96±0.1; p>0.05, one-way ANOVA) was found. The immunoreactivity of total and surface DAT in Y470A-hDAT was undetectable (data not shown). Similarly, as shown in Fig. 4b , despite no differences in the ratio of surface DAT to total DAT between WT (1.0±0.05), Y88F-hDAT (1.13±0.13; p>0.05, one-way ANOVA) and K92M-hDAT (1.09±0.09; p > 0.05, one-way ANOVA), the absolute total DAT in K92M-hDAT was significantly decreased compared to WT hDAT (t (8) =4.6, p<0.01, unpaired Student's t test). Thus, the decreased DA uptake in K92M-hDAT is not due to alteration of the available DAT on the cell surface.
Mutations of Tyr88, Lys92 and Tyr470 Differentially Influence Tat-Induced Inhibitory Effects on DA Transport
We have reported that mutation of either Tyr470 in hDAT or Cys22 in Tat attenuated Tat-induced decrease in DA uptake (Zhu et al. 2009; Midde et al. 2013) . To determine whether Y470F-hDAT and Y470A-hDAT show differential effects on Tat-induced decrease in DA uptake, we examined the specific [ 3 H]DA uptake in WT hDAT and the Tyr470 mutants in the presence or absence of recombinant Tat 1-86 or recombinant Tat Cys22. As shown in Fig. 5a , two-way ANOVA on the specific [ 3 H]DA uptake in WT hDAT and Tyr470 mutants revealed a significant main effect of mutation (F (2, 36) =88.1; p<0.001) and Tat treatment (F (2, 36) =15.5; p<0.001), as well as a significant mutation × Tat interaction (F (4, 36) =5.2; p<0.01). Tat (250 nM, final concentration) decreased the V max of [ 3 H]DA uptake by 32 % in WT hDAT (F (1, 8) =23.6; p<0.01) and by 47 % in Y470F-hDAT (F (1, 8) =15.4; p<0.01), respectively; however, no effect of Tat was observed in Y470H-hDAT (p>0.05) and Y470A-hDAT (p>0.05), suggesting that the different substitutions at Tyr470 residue in hDAT differentially influence Tat-induced inhibition of DA uptake. In addition, Tat Cys22 (500 nM, final concentration) did not alter DA uptake in WT hDAT and three Tyr470 mutants compared to their respective controls, suggesting that Cys22 residue in Tat plays a critical role in Tat-induced regulation DAT function (Fig. 5a ). We also determined the effects of Y88F-hDAT and K92M-hDAT on Tat-induced inhibition of DA uptake (Fig. 5b) . A two-way ANOVA on the specific [ 3 H]DA uptake revealed a significant main effect of mutation (F (2, 54) =124; p<0.001) and Tat treatment (F (2, 54) =4.7; p<0.05); however, mutation × Tat interaction (F (4, 54) =1.9; p>0.05) was not significant. Exposure to Tat decreased the V max of [ 3 H]DA uptake by 32 % in WT hDAT (F (1, 12) =8.0; p<0.05; Fig. 5b) ; however, no effect of Tat was observed in Y88F-hDAT (F (1, 12) =1.1; p>0.05) and K92M-hDAT (F (1, 12) =1.4; p>0.05), suggesting that mutation of either Tyr88 or Lys92 in hDAT attenuates Tatinduced reduction of hDAT function. With regard to the effect of recombinant Tat Cys22 on DA uptake (Fig. 5b) (Loland et al. 2003) . Addition of Zn 2+ is able to partially reverse an inward-facing state to an outward-facing state (Norregaard et al. 1998; Loland et al. 2003 Fig. 6a , two-way ANOVA on the specific [ 3 H]DA uptake in WT and Y470F-hDAT and Y470A-hDAT revealed a significant main effect of mutation (F (2, 18) =99; p<0.001), zinc (F (1, 18) =40; p<0.001) and a significant mutation × zinc interaction (F (2, 18) =8.9; p<0.01). The addition of Zn 2+ significantly decreased [ 3 H]DA uptake in WT hDAT, Y470F-hDAT and Y470A-hDAT by 47, 49 and 72 %, respectively (Fig. 6a , ps< 0.01 relative to control, unpaired Student's t test), suggesting these mutants do not affect Zn 2+ -mediated regulation of DA transport. In contrast, as shown in Fig. 6b, a two- H]DA (in the presence of 10 μM nomifensine, final concentration) was subtracted from total uptake to calculate DATmediated uptake. * p < 0.05 compared to control value (unpaired Student's t test) (n=5). b Cell surface expression of WT hDAT, Y88F-hDAT and K92M-hDAT was analyzed by biotinylation assay. Top panel: representative immunoblots in CHO cells expressing WT hDAT (WT), Y88F-hDAT (Y88F) or K92M-hDAT (K92M). Bottom panel: DAT immunoreactivity is expressed as mean ± S.E.M. densitometry units from three independent experiments (n=3). * p<0.05 compared to WT hDAT (unpaired Student's t test)
With regard to Y88F-hDAT and K92M-hDAT (Fig. 7a) , a two-way ANOVA on the specific [ 3 H]DA uptake revealed a significant main effect of mutation (F (1, 24) =170; p<0.001), zinc (F (1, 24) =102; p<0.001) and a significant mutation × zinc interaction (F (2, 24) =8.3; p<0.01). The addition of Zn 2+ significantly decreased [ 3 H]DA uptake in WT and Y88F-hDAT and K92M-hDAT by 48, 73 and 81 %, respectively (ps<0.001 relative to control, unpaired Student's t test). In addition, twoway ANOVA on the specific [ 3 H]WIN35,428 binding in WT and Y88F-hDAT and K92M-hDAT revealed a significant main effect of mutation (F (1, 18) =5.3; p<0.05), zinc (F (1, 18) =5.1; p<0.05); however, significant mutation × zinc interaction (F (2, 18) =0.7; p>0.05) was not significant (Fig. 7b) ]DA revealed significant main effects of mutation (F (3, 11) =41.7; p<0.001), time (F (5, 55) =355.9; p<0.001) and a significant mutation × time interaction (F (15,55) =40.5; p<0.001). Post-hoc analyses showed that compared to WT hDAT, DA efflux levels were elevated at 1, 10, 20 min in Y470H-hDAT and at 1 and 10 min in Y470A-hDAT (ps<0.05, Bonferroni t-test). With regard to MPP + efflux (Fig. 6d) , a two-way ANOVA revealed significant main effects of mutation (F (3, 12) =18.1; p<0.001), time (F (5, 60) =389.5; p<0.001) and significant mutation × time interaction (F (15, 60) = 8.6; p < 0.001) for Y470F-hDAT, Y470H-hDAT and Y470A-hDAT compared to WT hDAT. Compared to WT hDAT, DA efflux levels were elevated in Y470H-hDAT and Y470A-hDAT at all-time points (ps<0.05, Bonferroni t-test). As shown in Fig. 7c , a two-way ANOVA on the basal efflux of [ 3 H]DA in Y88F-hDAT and K92M-hDAT revealed significant main effects of mutation (F (2, 6) = 28.1; p<0.01), time (F (5, 30) =156; p<0.001) and significant mutation × time interaction (F (10, 30) =511; p<0.001). Posthoc analysis revealed that compared to WT hDAT, DA efflux levels were elevated at 1 and 10 min in K92M-hDAT (p<0.05, Bonferroni t-test) but not in Y88F-hDAT. Compared to WT hDAT, Y88F and K92M mutants did not alter the basal efflux of [
H]MPP
+ at all-time points (Fig. 7d) .
Discussion
We have recently demonstrated that mutation of Tyr470 of hDAT is critical for HIV-1 Tat-induced inhibition of DA transport and transporter conformational transitions (Midde et al. 2013) . Through computational modeling and MD simulations, we identified that the residue Tyr470 is a key component of a hydrophobic region, which is important for stabilizing the compact structure of hDAT and maintaining DA transport. In addition, through hydrophobic or electrostatic intramolecular interactions, Tyr88 and Lys92, two relevant residues of hDAT, help to stabilize the compact structure of hDAT. Mutations of Tyr88, Lys92 or Tyr470 attenuated Tat-induced inhibition of DA transport, demonstrating the functional relevance of these residues for Tat binding to hDAT. binding, their surface DAT expression was not altered, suggesting that the decreased V max in these mutants is not due to DAT internalization. We have demonstrated that Y470H exhibits a reduction of the V max with no changes in K m (Midde et al. 2013) ; however, the current data show that Y470A but not Y470F decreased the V max without changing K m value because Y470F did not affect the hydrophobic property of Y470. These data support the computational prediction that Tyr 88, Lys 92 and Tyr 470, via interacting with TM1b and TM6a helices movement, stabilize DA transport function (Fig. 2) . Mutations of these residues could disrupt the intermolecular interactions within DAT, thereby decreasing DA transport. On the other hand, mutations of these residues without changing K m for DA uptake suggest that these residues in DAT for Tat binding do not overlap with the binding site of substrate DA (Midde et al. 2013) . In contrast, K92M had an increase in the DA uptake potency of cocaine, GBR12909 and WIN35,428, whereas Y88F only increased the potency of cocaine and GBR12909. With regard to the potency for [ 3 H]WIN35,428 binding, Y88F and K92M increased IC 50 value of DA, whereas only Y88F decreased IC 50 of cocaine. These data are consistent with our previous finding showing an increase in the DA uptake potency of cocaine and GBR12909 in Y470H (Midde et al. 2013 ). GBR12909 labels the classic DA uptake site in rodent brain, binding to the piperazine acceptor site (Andersen et al. 1987) , while cocaine competes with DA uptake and preferentially stabilizes the hDAT in the outward-facing conformational state, resulting in a reduction of DA uptake (Reith et al. 2001; Loland et al. 2002) . We have demonstrated that Tat allosterically modulates DAT function (Zhu et al. 2011) . Therefore, Tyr88, Lys92 and Tyr470 predicted by computational modeling represent the intermolecular binding sites in DAT for Tat and mutations of these residues may, via allosteric DAT modulation and conformational transitions, increase their potency of cocaine and GBR12909 inhibiting DA uptake and WIN binding. Recent studies have demonstrated that Tat and cocaine synergistically inhibit DAT function in vitro and in vivo (Ferris et al. 2008; Harrod et al. 2008; Paris et al. 2014) . Thus, the current findings support our hypothesis that Tat, via allosteric modulation of DAT function, potentiates cocaine-mediated inhibitory effects on DA transport.
We have demonstrated that the Tat molecule is associated with DAT through intermolecular electrostatic attractions and complementary hydrophobic interactions (Midde et al. 2013) . Further, the hDAT-Tat binding mode (Fig. 1) predicted that eliminating the cation-π interaction between Tyr470 in hDAT and T-M1 in Tat by mutating Y470 into a nonaromatic residue such as histidine or alanine would significantly weaken the binding between hDAT and Tat. Our previous study has demonstrated that mutating Tyr470 to histidine attenuates Tat-induced inhibitory effect on DA uptake (Midde et al. 2013 ). The present results show that Y470A but not Y470F also attenuated Tat-induced inhibition on DAT because mutating Tyr470 to phenylalanine (Y470F) does not affect the cation-π interaction. These findings indicate that the important role of Tyr470 in Tat-DAT interaction. In addition, in light of the Tat-DAT binding structure (Fig. 2) , mutating Tyr88 or Lys92 to the residues without hydrogen-bonding capacity would diminish the binding affinity of Tat-DAT. The computational predictions were validated by experimental data showing that Y88F and K92M attenuate Tat-induced inhibition of DAT. In support of the Tat-DAT interaction model, the present results also demonstrate that mutation of Cys22 in Tat eliminates the inhibitory effect of wild type Tat on DA transport in WT hDAT and mutants, suggesting that the Cys22 residue is critical for Tat binding to DAT. Evidence shows that the cysteine rich domain (residues 22-37) in the first exon of Tat protein is critical for the biological function of Tat (Debaisieux et al. 2012; Bertrand et al. 2013 ). Our previous studies have demonstrated that mutation of Tat Cys22 had no effect on DAT function (Zhu et al. 2009; Midde et al. 2013) . Understanding the functional relevance of additional residues in Tat on modulation of DAT will provide useful feedback for further refining the computationally predicted binding model of the DAT with Tat. These findings further support that the integrated computational-experimental studies is fairly reliable for identifying the recognition binding sites on hDAT for Tat and cocaine interaction.
Tat has been shown to allosterically modulate DAT function (Zhu et al. 2009; Zhu et al. 2011 ). The allosteric modulation of DAT is responsible for conformational transitions via substrate-and ligand-binding sites on DAT Shan et al. 2011) . Mutation of Tyr470 (Y470H) leads to transporter conformational transitions by affecting zinc modulation of DA uptake and WIN binding as well as enhancing basal DA efflux (Midde et al. 2013 (Norregaard et al. 1998) . One possible explanation for the failure to reverse Zn 2+ influence on DA uptake in these mutants could be due to less effect of these particular mutations on hydrogen bonds between Zn 2+ and coordination residues, which is necessary for zinc-binding with outward-open state of DA transport (Alberts et al. 1998 binding by these mutants reveal one aspect of DAT conformational changes. The effect of mutations on conformational states of DAT was further validated by measuring basal substrate efflux. The present study confirmed Y470H-mediated enhancement of basal DA and MPP + efflux, which is consistent with our previous report (Midde et al. 2013) . Interestingly, mutant Y470A produces a similar increase in basal efflux levels for both DA and MPP + , whereas Y470F had no effect on both DA and MPP + efflux. With regard to mutations of Tyr88 and Lys92, only K92M displayed an increase in basal efflux of DA but not MPP + . Nevertheless, the current results demonstrate the differential influences of DAT residues in the basal substrate efflux. We have demonstrated that Tat protein enhances DA efflux in WT hDAT (Midde et al. 2013) . Thus, to fully understand the mechanisms by which Tat inhibits DAT function, future studies including amphetaminestimulated efflux and MTSET will be necessary to further analyze the changes in the conformational transition attributed to the identified residues in DAT.
In summary, we have identified the residues Tyr470, Tyr88 and Lys92 as the specific recognition binding sites in DAT for Tat binding, as well as the molecular mechanism(s) that underlies how Tat, via these residues, allosterically modulates DA translocation. Considering that the dynamic and complex interactions between Tat and DAT involve multiple residues of DAT, testing the influence of multiple DAT mutations in Tat and DAT interaction in vitro and in vivo is an essential task in our future study. Our studies will provide a mechanistic basis to identify targets on the DAT for developing compounds that specifically block Tat binding site(s) in hDAT, thereby stabilizing physiological DA neurotransmission and improving neurocognitive function of HAND in concurrent cocaine abusers.
